Mycenax Biotech Inc.(TW:4726)
NT$22.40-0.60 (-2.61%)
TW:4726
Mycenax Biotech Inc. financials statements
NT$22.40
At close:-0.60 (-2.61%)
Mycenax Biotech Inc. (4726) Ratios
Mycenax Biotech Inc. Ratios
TW:4726's free cash flow for Q2 2026 was NT$107.12M. For the 2026 fiscal year, TW:4726's free cash flow was decreased by NT$-5.79M and operating cash flow was NT$112.91M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.55 | 1.11 | 1.46 | 3.03 | 1.66 |
| Quick Ratio | 0.43 | 1.02 | 1.31 | 2.64 | 1.34 |
| Cash Ratio | 0.20 | 0.41 | 0.69 | 2.08 | 0.53 |
| Solvency Ratio | -0.10 | -0.12 | -0.28 | -0.13 | 0.06 |
| Operating Cash Flow Ratio | -0.02 | -0.29 | -0.17 | -0.24 | -0.27 |
| Short-Term Operating Cash Flow Coverage | -0.06 | -1.14 | -1.04 | -0.73 | -2.23 |
| Net Current Asset Value | NT$ -1.05B | NT$ -608.52M | NT$ -225.20M | NT$ 576.36M | NT$ -334.94M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.33 | 0.26 | 0.19 | 0.21 | 0.24 |
| Debt-to-Equity Ratio | 0.67 | 0.44 | 0.30 | 0.31 | 0.39 |
| Debt-to-Capital Ratio | 0.40 | 0.30 | 0.23 | 0.24 | 0.28 |
| Long-Term Debt-to-Capital Ratio | 0.21 | 0.23 | 0.18 | 0.17 | 0.20 |
| Financial Leverage Ratio | 2.04 | 1.66 | 1.54 | 1.43 | 1.65 |
| Debt Service Coverage Ratio | -0.22 | -0.68 | -2.21 | -0.67 | 1.18 |
| Interest Coverage Ratio | -11.99 | -15.43 | -22.10 | -21.49 | -36.42 |
| Debt to Market Cap | 0.14 | 0.09 | 0.09 | 0.14 | 0.10 |
| Interest Debt Per Share | 5.35 | 4.43 | 3.67 | 5.90 | 5.03 |
| Net Debt to EBITDA | -7.09 | -4.50 | -0.61 | 2.29 | 5.53 |
| Profitability Margins | |||||
| Gross Profit Margin | -24.51% | -35.29% | -57.49% | -15.52% | 17.77% |
| EBIT Margin | -54.56% | -64.29% | -100.25% | -60.58% | -10.98% |
| EBITDA Margin | -16.15% | -19.95% | -52.02% | -21.90% | 10.70% |
| Operating Profit Margin | -54.56% | -67.48% | -92.26% | -56.33% | -11.90% |
| Pretax Profit Margin | -61.35% | -68.66% | -104.81% | -63.21% | -11.30% |
| Net Profit Margin | -60.61% | -68.30% | -104.63% | -61.95% | -11.61% |
| Continuous Operations Profit Margin | -60.61% | -68.30% | -104.63% | -61.95% | -11.61% |
| Net Income Per EBT | 98.79% | 99.48% | 99.83% | 98.01% | 102.67% |
| EBT Per EBIT | 112.45% | 101.76% | 113.60% | 112.21% | 94.98% |
| Return on Assets (ROA) | -13.76% | -13.87% | -18.11% | -10.19% | -2.86% |
| Return on Equity (ROE) | -28.06% | -23.09% | -27.90% | -14.61% | -4.71% |
| Return on Capital Employed (ROCE) | -18.74% | -17.05% | -19.96% | -10.80% | -3.55% |
| Return on Invested Capital (ROIC) | -14.94% | -15.79% | -18.94% | -9.95% | -3.42% |
| Return on Tangible Assets | -13.93% | -14.02% | -18.32% | -10.30% | -2.92% |
| Earnings Yield | -6.87% | -5.22% | -9.45% | -7.32% | -1.60% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.33 | 4.61 | 11.15 | 3.17 | 2.33 |
| Payables Turnover | 11.90 | 26.72 | 23.33 | 16.11 | 11.64 |
| Inventory Turnover | 6.94 | 14.25 | 9.15 | 3.43 | 3.67 |
| Fixed Asset Turnover | 0.34 | 0.30 | 0.28 | 0.34 | 0.39 |
| Asset Turnover | 0.23 | 0.20 | 0.17 | 0.16 | 0.25 |
| Working Capital Turnover Ratio | -3.53 | 3.26 | 0.80 | 0.89 | 3.04 |
| Cash Conversion Cycle | 90.49 | 91.19 | 56.98 | 198.85 | 224.60 |
| Days of Sales Outstanding | 68.54 | 79.24 | 32.74 | 115.06 | 156.59 |
| Days of Inventory Outstanding | 52.63 | 25.62 | 39.89 | 106.45 | 99.35 |
| Days of Payables Outstanding | 30.68 | 13.66 | 15.64 | 22.66 | 31.35 |
| Operating Cycle | 121.17 | 104.85 | 72.63 | 221.51 | 255.94 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.13 | -0.93 | -0.64 | -0.91 | -0.98 |
| Free Cash Flow Per Share | -0.61 | -2.53 | -2.09 | -4.77 | -8.48 |
| Dividend Paid and CapEx Coverage Ratio | -0.27 | -0.58 | -0.44 | -0.24 | -0.13 |
| Capital Expenditure Coverage Ratio | -0.27 | -0.58 | -0.44 | -0.24 | -0.13 |
| Operating Cash Flow Coverage Ratio | -0.03 | -0.22 | -0.18 | -0.16 | -0.20 |
| Operating Cash Flow to Sales Ratio | -0.04 | -0.28 | -0.20 | -0.21 | -0.19 |
| Free Cash Flow Yield | -1.93% | -5.84% | -5.94% | -12.73% | -22.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -14.56 | -19.20 | -10.59 | -13.69 | -62.13 |
| Price-to-Sales (P/S) Ratio | 8.83 | 13.07 | 11.07 | 8.47 | 7.27 |
| Price-to-Book (P/B) Ratio | 4.09 | 4.42 | 2.95 | 2.00 | 2.95 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -51.72 | -17.12 | -16.85 | -7.86 | -4.47 |
| Price-to-Operating Cash Flow Ratio | -239.82 | -46.64 | -55.07 | -41.28 | -38.48 |
| Price-to-Earnings Growth (PEG) Ratio | 3.66 | 0.60 | -0.50 | -0.04 | 0.18 |
| Enterprise Value Multiple | -61.75 | -70.02 | -21.89 | -36.38 | 73.46 |
| Enterprise Value | 7.38B | 9.55B | 7.43B | 5.83B | 6.09B |
| EV to EBITDA | -61.75 | -70.02 | -21.89 | -36.38 | 73.46 |
| EV to Sales | 9.97 | 13.97 | 11.39 | 7.97 | 7.86 |
| EV to Free Cash Flow | -58.43 | -18.30 | -17.33 | -7.39 | -4.83 |
| EV to Operating Cash Flow | -270.93 | -49.84 | -56.65 | -38.84 | -41.61 |
| Tangible Book Value Per Share | 7.54 | 9.65 | 11.70 | 18.48 | 12.45 |
| Shareholders’ Equity Per Share | 7.73 | 9.82 | 11.91 | 18.78 | 12.84 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.01 | 0.00 | 0.02 | -0.03 |
| Revenue Per Share | 3.58 | 3.32 | 3.18 | 4.43 | 5.21 |
| Net Income Per Share | -2.17 | -2.27 | -3.32 | -2.74 | -0.61 |
| Tax Burden | 0.99 | 0.99 | 1.00 | 0.98 | 1.03 |
| Interest Burden | 1.12 | 1.07 | 1.05 | 1.04 | 1.03 |
| Research & Development to Revenue | 0.10 | 0.11 | 0.12 | 0.20 | 0.12 |
| SG&A to Revenue | 0.16 | 0.21 | 0.23 | 0.21 | 0.17 |
| Stock-Based Compensation to Revenue | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 |
| Income Quality | 0.06 | 0.41 | 0.19 | 0.32 | 1.67 |
Currency in TWD
